#biotech
18 stories
Alteogen Secures $149M Investment
Korean biotech Alteogen lands $149M convertible funding from state-backed investors to expand manufacturing and license drug technologies.
Dealroom · 1m
Intero Biosystems replaces animal drug tests with lab-grown guts
A Denver startup is selling mini human intestines to drugmakers, offering an alternative to animal testing that better predicts how drugs will work in people.
TechCrunch · 2m
Rubedo's cream shows skin can age backwards
A topical drug targeting senescent cells reduced skin's biological age by two years in early trials, though experts urge caution about what aging clocks actually measure.
WIRED · 1m
Is Europe ready for the next pandemic?
Five years after Covid, the EU assesses its preparedness for future health crises amid questions about coordination and innovation priorities.
POLITICO · 1m
Pyxis Oncology Stock Bullish
Pyxis Oncology's MICVO drug shows promise for cancer treatment.
Seekingalpha · 1m
Viking Soars Alone as Obesity Complex Shrugs
Viking Therapeutics jumps 26.5% after GLP-1 results while obesity peers barely move.
24/7 Wall St. · 1m
Dr Lal PathLabs Acquires SN Genelab Stake
Dr Lal PathLabs to buy 70% stake in SN Genelab for Rs 168 crore.
The Economic Times · 1m
Enveda raises $311M to test AI-found drugs
The biotech startup that hunts medicines in nature just doubled its valuation with fresh funding for clinical trials.
TechCrunch · 1m
PTC Therapeutics Rises 5.5% in Biotech Rally
Biotech stocks surge as sector-wide momentum lifts PTC Therapeutics 5.5%.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
Moderna Rises 6% in Biotech Rally
Moderna jumps 6% as biotech stocks surge in coordinated sector move
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
Acadia Pharmaceuticals Stock Plummets After Clinical Failure
Acadia Pharmaceuticals shares drop 8.6% after remlifanserin trial misses primary endpoint
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
Can Zenas BioPharma justify its $108M quarterly burn?
A clinical-stage biotech with $673.9M in cash races toward an FDA decision that will make or break its future.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 2m
Anthropic's wet lab tests AI biology theories in real experiments
The AI safety company is running physical biology experiments to validate its models' disease-fighting potential, raising questions about its dual focus on safety and capability.
TechCrunch · 1m
Evvy raises $40M to fix the data gap in women's health
A $40M Series B bets that vaginal microbiome data can answer questions medicine keeps calling unexplained.
TechCrunch · 2m
Colossal's Ben Lamm takes the Disrupt stage
De-extinction is now a billion-dollar startup bet, and Disrupt 2026 puts the hardest question about it on stage.
TechCrunch · 1m · 8 views
Amgen fell on someone else's failed drug
Novartis missed on pelacarsen, and $12 billion came off Amgen for a bet it hasn't run yet.
Yahoo Finance · 1m
AlphaGenome Atlas: DeepMind's Map of 9 Billion Genetic Mutations
Google DeepMind's 1-petabyte database maps the impact of every possible single-letter DNA mutation, accelerating rare disease and genomic research.
Google · 1m
Inside RonanRx: Software-Driven Custom GLP-1 Manufacturing
RonanRx is vertically integrating telehealth, software, and drug compounding to deliver personalized, affordable GLP-1 treatments.
Hacker News · 1m